Here's why the Medlab (ASX:MDC) share price is rising today

The Medlab Clinical Ltd (ASX: MDC) share price is treading upwards today after announcing an agreement Arrotex. Here's what you need to know.

| More on:
high share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medlab Clinical Ltd (ASX: MDC) share price is on the rise in mid-afternoon trade. This comes after the company announced an agreement with Australia's largest generic and over the counter pharmaceutical company, Arrotex.

Consequently, at the time of writing, the Medlab share price is fetching 34 cents apiece, up 3.08%.

Below, we take a closer look at the deal between Medlab and Arrotex.

Milestone agreement

Medlab shares are in the green today after reporting an important agreement that will unlock new opportunities for the company.

According to its release, Medlab advised it has entered an exclusive non-binding Heads of Agreement (HoA) with Arrotex.

Under the deal, Arrotex will assist Medlab in accelerating its cannabinoid formulation NanoCBD for development and distribution to Australian pharmacies. This will include fast-tracking its final application with the Therapeutic Goods Administration (TGA). Medlab hopes to position NanoCBD for pharmacist only medicines schedule (S3).

Interestingly, the HoA is the first time a pharma and biotech have formed a partnership to explore medical cannabis prospects in Australia.

The contract, which will include commercial terms, is expected to be finalised before 1 July 2021.

What did management say?

Medlab CEO Dr. Sean Hall hailed the new agreement, saying:

This is a major milestone for both the Australian market and the budding partnership between Medlab and Arrotex. Unlike many CBD producers, Medlab can deliver to the pharmaceutical standards required for TGA approval and this partnership will now enable direct application into clinical practice through Arrotex's extensive network. There is a clear alignment within both companies to deliver a superior, approved CBD product to Australian patients.

Dr. Hall went on to speak about the company's novel medicinal candidate, NanoCBD. He added:

A key differentiator of NanoCBD is the proprietary delivery platform NanoCelle that provides faster and more effective absorption of active ingredients into the bloodstream, without the need for needles or pills. It is a commercially viable platform that offer unique opportunities for partnering with some of the biggest players in the pharma industry.

How has the Medlab share price performed?

Shares in Medlab have been on a rollercoaster ride over the past 12 months, riding on volatile swings. Despite the company's shares being up a mediocre 11% since this time last year, Medlab has mostly recovered compared to its pre-COVID highs.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Broker looking at the share price.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Rising share price chart.
Share Gainers

Why Core Lithium, Goodman, GQG, and Macquarie shares are pushing higher today

These shares are starting the week in a positive fashion. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Mergers & Acquisitions

Guess which ASX stock just rocketed 21% on takeover news

Investors are piling into the ASX stock following a confirmed takeover offer.

Read more »

Three guys in shirts and ties give the thumbs down.
Share Market News

Why AVITA, Botanix, Brainchip, and NAB shares are falling today

These shares are falling on Monday. But why?

Read more »

Three smiling corporate people examine a model of a new building complex.
Share Market News

Pexa affirms 2025 guidance but issues warning on costs

Let's see what the property technology company has announced today.

Read more »

A man sitting at his desktop computer leans forward onto his elbows and yawns while he rubs his eyes as though he is very tired.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Happy woman holding white house model in hand and pointing to it with a pen.
Share Market News

Domain shareholders rejoice after CoStar snaps it up for a large premium

It's a good week to be a Domain shareholder.

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

A decent start to the week is expected for Aussie investors.

Read more »